Organization | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Madrid Spain (2001)

Organization Overview

First Clinical Trial

2008

NCT00716391

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Active Ingredients

Drugs in Phase 3 Trials (1)

cisplatin (platinol) (4 trials)

Drugs in Phase 2 Trials (9)

cetuximab (erbitux) (4 trials)

docetaxel (taxotere) (2 trials)

dostarlimab (Jemperli) (1 trial)

fluorouracil (efudex) (2 trials)

niraparib (zejula) (1 trial)

nivolumab (opdivo) (1 trial)

paclitaxel (taxol) (3 trials)

panitumumab (vectibix) (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Squamous Cell (Phase 2)

Head and Neck Neoplasms (Phase 2)

Laryngeal Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 10